Chronic Liver Disease patients are at-high-risk of developing HCC
Regular screening can help detect HCC at an early stage when treatment is more effective and outcomes are better
Early Detection
Surveillance is important for individuals with hepatitis infection, cirrhosis, or a family history of liver cancer.
Monitoring High-Risk Individuals
Surveillance helps healthcare providers make informed decisions about treatment options and strategies.
Guiding Treatment Decisions
Detecting HCC with better modalities reduces costs associated with treatment and improves quality of life.
Reducing Healthcare Costs
Offering Novel Ways to Detect Cancer
Tvaster's technology seamlessly combines epigenetics, liquid biopsy and ddPCR for efficient cancer screening
Diagnose
Determine genetic and epigenetic alterations using, a simple blood based, minimally invasive test
Understand
Based on the diagnosis, determine the risk mitigation strategies
Decide
Make informed decisions based on genetic and epigenetic markers for personalised healthcare decisions
Solving real world problem. Developed by scientists and clinicians
Tvaster's scientists closely work with leading clinicians and oncologists to deliver solutions to real-world problems
2
Year of Operations
1000+
Patients Tested
5
Publications
3
Industry Awards
4
Clinical Studies
Young Investigator Award from International Liver Transplant Society
ILTS has awarded Tvaster Genkalp the "Young Investigator Award" for the work titled "INTEGRATION OF A NOVEL LIQUID BIOPSY-BASED METHYLATION PROFILING PLATFORM WITH ARTIFICIAL INTELLIGENCE ENABLES BCLC STAGING". The work focuses on using Episcreen Liver for Hepatocellular Carcinoma staging. The 2024 Annual Congress of ILTS is scheduled for May 1st to 4th in Houston, USA.
​